Rosalind Advisors’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.26M Buy
2,000,000
+1,750,000
+700% +$7.78M 2.97% 11
2026
Q2
$1.04M Hold
250,000
– – 0.39% 28
2026
Q1
$1.04M Buy
+250,000
New +$1.01M 0.42% 31

Other funds holding AQST

Rosalind Advisors's AQST Position: Q3 2026 in Review

Rosalind Advisors increased its Aquestive Therapeutics (AQST) stake by 700% in Q3 2026, buying an estimated $7.78M and bringing the position to 2,000,000 shares worth $9.26M. The position accounts for 2.97% of the portfolio, ranked #11.

Rosalind Advisors first reported a position in AQST in Q1 2026 and has held it in 3 quarters since. 188 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Rosalind Advisors held 2,000,000 shares of Aquestive Therapeutics worth $9.26M as of Q3 2026.
  • Rosalind Advisors bought 1,750,000 Aquestive Therapeutics shares in Q3 2026, an estimated $7.78M.
  • Aquestive Therapeutics made up 2.97% of Rosalind Advisors's portfolio in Q3 2026, its #11 holding.
  • Rosalind Advisors first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 188 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Rosalind Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.